Post COVID-19 interstitial lung disease- A review
Abstract
The novel Coronavirus SARS-CoV-2 that broke out in December 2019 became the main source of morbidity and mortality around the world. As efficient vaccines and medicines started to emerge , it became necessary to recognize and proactively deal with the long term respiratory difficulties that arise due to extreme illness. Patients with extreme Coronavirus pneumonia have the tendency of advancing to Interstitial Lung Diseases (ILD) and persistent pulmonary vascular disease. In this paper, we shortly review the pathophysiology of interstitial lung disease (ILD), lung injury resulting from serious Coronavirus disease. We also outline the potential viral and secure intervention processes for stopping the advancement of Post-Coronavirus pulmonary Fibrosis (PCPF). Post-Coronavirus pulmonary fibrosis is presently treated in only symptomatic patients, which is, to a great extent, a neglected perspective. Before this lethal illness can be treated, it has to be fully researched clinically in order to know its danger in Coronavirus survivors. Strong clinical and research biomarkers ought to be considered in order to know the subgroup of patients that will deteriorate or advance to post Coronavirus interstitial lung disease. Customized medication is a decent method that can be used to treat patients with Post Coronavirus interstitial lung diseases.References
Peter M, Athol U, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet. 2002;138:805–15.
George P, Patterson C, Ak R. Lung transplantation for idiopathic pulmonary fibrosis. Lancet Respir Med. 2019;7(3):271–82.
Carfì A, Bernabei R, Landi F. For the Gemelli against COVID-19 post-acute care study group. Persistent symptoms in patients after acute COVID-19. J Am Med Assoc. 2020;324(6):603–05.
King CS, Nathan SD. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respir Med. 2017;5(1):72–84.
Richeldi L, Du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2104; 370(22):2071–82.
King Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med, 2014; 370:2083–92.
Udwadia ZF, Pokhariyal PK, Tripathi AK, Kohli A. Fibrotic interstitial lung disease occurring as sequelae of COVID-19 pneumonia despite concomitant steroids. Lung India. 2021; 38(1):1–105.
Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020;20(19):1134-40
Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2021; 180(7):934–43. DOI: 10.1001/jamainternmed.2020.0994.
Diao B, Wang C, Wang R, Feng Z, Zhang J, Yang H, et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Comm.2020. DOI: 10.1101/2020.03.04.20031120.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–80.
Zhao W, Zhong Z, Xie X, Yu Q, Liu J. Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: a multicenter study. AJR Am J Roentgenol 2020;214: 1072–7.
Bradley BT, Maioli H, Johnston R, Chaudhry I, Fink SL, Xu H, et al. Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series. Lancet
;396:320–332.
Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19). Radiology. 2020;295:715–21.
Wang Y, Dong C, Hu Y, Li C, Ren Q, Zhang X, Shi H, Zhou M. Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: a longitudinal study. Radiology 2020;296:E55–E64.
CDC, 2019. Available from URL: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html.
US Department of Health and Human Services. Guidance on “long COVID†as a disability under the ADA, Section 504 and Section 1557. HHS. Gov. 2021.
Wong AW, Fidler L, Marcoux V, Johannson KA, Assayag D, Fisher JH, et al. Practical considerations for the diagnosis and treatment of fibrotic interstitial lung disease during the coronavirus disease 2019 pandemic. Chest. 2020;158:1069–78.
Antoniou KM, Raghu G, Tzilas V, Bouros D. Management of patients with interstitial lung disease amid the COVID-19 pandemic. Respiration. 2020; 99: 625–7.
Wang Y, Dong C, Hu Y, Li C, Ren Q, Zhang X, Shi H, Zhou M. Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: A longitudinal study. Radiology. 2020; 296: E55–E64.
Deng L, Khan A, Zhou W, Dai Y, Eftekhar M, Chen R, Cheng G. Follow-up study of clinical and chest CT scans in confirmed COVID-19 patients. Radiol Infect Dis. 2020;7(3):106-13
Barisione E, Grillo F, Ball L, Bianchi R, Grosso M, Morbini P, et al. Fibrotic progression and radiologic correlation in matched lung samples from COVID-19 post-mortems. Virchows Archiv. 2020;478(3):471-85
Huang W, Wu Q, Chen Z, Xiong Z, Wang K, Tian J, Zhang S. The potential indicators for pulmonary fibrosis in survivors of severe COVID-19. J Infec. 2021;82(2):e5-7..
Revel MP, Parkar AP, Prosch H, Silva M, Sverzellati N, Gleeson F, Brady A. The European Society of Radiology (ESR); The European Society of Thoracic Imaging (ESTI). COVID-19 patients and the radiology department—Advice from the European Society of Radiology (ESR) and the European Society of Thoracic Imaging (ESTI). Eur Radiol. 2020, 30: 4903–9.
Li Y, Wu J, Wang S, Li X, Zhou J, Huang B, et al. Progression to fibrosing diffuse alveolar damage in a series of 30 minimally invasive autopsies with COVIDâ€19 pneumonia in Wuhan, China. Histopathology. 2021;78(4):542-55.
Ojo AS, Balogun SA, Williams OT, Ojo OS. Pulmonary fibrosis in COVID-19 survivors: Predictive factors and risk reduction strategies. Pulm Med. 2020;6175964.
George PM, Barratt SL, Condliffe R, Desai SR, Devaraj A, Forrest I, et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020;75(11):1009-16.
Scelfo C, Fontana M, Casalini E, Menzella F, Piro R, Zerbini A, et al. A dangerous consequence of the recent pandemic: Early lung fibrosis following COVID-19 pneumonia—Case reports. Ther Clin Risk Manag. 2020;16:1039–46.
Combet M, Pavot A, Savale L, Humbert M, Monnet X. Rapid onset honeycombing fibrosis in spontaneously breathing patient with COVID-19. Eur Respir J. 2020; 56.
Tale S, Ghosh S, Meitei SP, Kolli M, Garbhapu AK, Pudi S. Post-COVID-19 pneumonia pulmonary fibrosis. QJM: Int J Med. 2020;113(11):837-8.
Vasarmidi E, Tsitoura E, Spandidos DA, Tzanakis N, Antoniou KM. Pulmonary fibrosis in the aftermath of the COVID-19 era (Review). Exp Ther Med. 2020; 20: 2557–60.
Cabrera-Benitez NE, Laffey JG, Parotto M, Spieth PM, Villar J, Zhang H, et al. Mechanical ventilation-associated lung fibrosis in acute respiratory distress syndrome: A significant contributor to poor outcome. Anesthesiology. 2014; 121: 189–198.
Cabrera-Benitez NE, Parotto M, Post M, Han B, Spieth PM, Cheng WE, et al. Mechanical stress induces lung fibrosis by the epithelial-mesenchymal transition. Crit Care Med. 2012; 40: 510–17.
Spagnolo P, Balestro E, Aliberti S, Cocconcelli E, Biondini D, Casa GD, et al. Pulmonary fibrosis secondary to COVID-19: A call to arms? Lancet Respir Med. 2020; 8: 750–52.
Otoupalova E, Smith S, Cheng G, Thannickal VJ. Oxidative stress in pulmonary fibrosis. Compr Physiol. 2020; 10:509–47.
Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA. 2020; 323: 2329–30.
Brochard L, Slutsky A, Pesenti A. Mechanical ventilation to minimize progression of lung injury in acute respiratory failure. Am J Respir Crit. Care Med. 2017; 195: 438–42.
Chen JY, Qiao K, Liu F, Wu B, Xu X, Jiao GQ, et al. Lung transplantation as a therapeutic option in acute respiratory distress syndrome for coronavirus disease 2019-related pulmonary fibrosis. Chin Med J. 2020; 133: 1390–96.
Antonio GE, Wong KT, Hui DS, Wu A, Lee N, Yuen EH, et al. Thin-section CT in patients with severe acute respiratory syndrome following hospital discharge: Preliminary experience. Radiology. 2003; 228: 810–15.
Zhang P, Li J, Liu H, Han N, Ju J, Kou Y, et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: A 15-year follow-up from a prospective cohort study. Bone Res. 2020; 8: 8.
Yu M, Liu Y, Xu D, Zhang R, Lan L, Xu H. Prediction of the development of pulmonary fibrosis using serial thin-section CT and clinical features in patients discharged after treatment for COVID-19 pneumonia. Korean J Radiol. 2020; 21: 746–55.
Mo X, Jian W, Su Z, Chen M, Peng H, Peng P, et al. Abnormal pulmonary function in COVID-19 patients at the time of hospital discharge. Eur Respir J. 2020;55.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Pakistan Journal of Chest Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
